MX2017000150A - ZEOLITE ACTIVATED AND MICRONIZED, AS A COADYUVANT IN THE TREATMENT OF UREMIA. - Google Patents
ZEOLITE ACTIVATED AND MICRONIZED, AS A COADYUVANT IN THE TREATMENT OF UREMIA.Info
- Publication number
- MX2017000150A MX2017000150A MX2017000150A MX2017000150A MX2017000150A MX 2017000150 A MX2017000150 A MX 2017000150A MX 2017000150 A MX2017000150 A MX 2017000150A MX 2017000150 A MX2017000150 A MX 2017000150A MX 2017000150 A MX2017000150 A MX 2017000150A
- Authority
- MX
- Mexico
- Prior art keywords
- micronized
- activated
- uric acid
- treatment
- zeolite
- Prior art date
Links
- 229910021536 Zeolite Inorganic materials 0.000 title abstract 4
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 title abstract 4
- 239000010457 zeolite Substances 0.000 title abstract 4
- 208000037157 Azotemia Diseases 0.000 title 1
- 208000009852 uremia Diseases 0.000 title 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 abstract 4
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 abstract 4
- 229940116269 uric acid Drugs 0.000 abstract 4
- 241000792859 Enema Species 0.000 abstract 2
- 201000001431 Hyperuricemia Diseases 0.000 abstract 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 abstract 2
- 239000004202 carbamide Substances 0.000 abstract 2
- 208000020832 chronic kidney disease Diseases 0.000 abstract 2
- 239000007920 enema Substances 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 2
- 230000007170 pathology Effects 0.000 abstract 2
- 239000000126 substance Substances 0.000 abstract 2
- 239000003463 adsorbent Substances 0.000 abstract 1
- 229940095399 enema Drugs 0.000 abstract 1
- 229940079360 enema for constipation Drugs 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La invención se refiere a una zeolita natural activada y micronizada, como coadyuvante en el tratamiento y la prevención de patologías asociadas con enfermedad renal crónica, hiperuricemia y ácido úrico elevado. Otro aspecto de la invención se refiere a la administración de la zeolita natural activada y micronizada como un enema evacuante; que comprende una cantidad efectiva de zeolita natural activada y micronizada para la disminución de los niveles de sustancias nitrogenadas, tales como urea y ácido úrico en el organismo. El método de la invención incluye la administración de la composición de la invención; la composición de la invención es rectalmente instilada en un paciente. El producto de la presente invención puede ser utilizado como adsorbente de sustancias nitrogenadas, tales como urea y ácido úrico, en numerosas patologías tales como con enfermedad renal crónica, hiperuricemia y ácido úrico elevado; mediante la elaboración de enemas evacuantes.The invention relates to a natural activated and micronized zeolite, as an adjunct in the treatment and prevention of pathologies associated with chronic kidney disease, hyperuricemia and elevated uric acid. Another aspect of the invention relates to the administration of the activated and micronized natural zeolite as an evacuating enema; It comprises an effective amount of activated and micronized natural zeolite for the reduction of the levels of nitrogenous substances, such as urea and uric acid in the body. The method of the invention includes the administration of the composition of the invention; The composition of the invention is rectally instilled in a patient. The product of the present invention can be used as an adsorbent of nitrogenous substances, such as urea and uric acid, in numerous pathologies such as with chronic kidney disease, hyperuricemia and elevated uric acid; by making evacuating enemas.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/MX2014/000095 WO2015199522A1 (en) | 2014-06-23 | 2014-06-23 | Activated and micronised zeolite as an adjuvant in the treatment of uremia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017000150A true MX2017000150A (en) | 2017-11-10 |
| MX386944B MX386944B (en) | 2025-03-19 |
Family
ID=54938502
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017000150A MX386944B (en) | 2014-06-23 | 2014-06-23 | ACTIVATED AND MICRONIZED ZEOLITE, AS AN ADJUVANT IN THE TREATMENT OF UREMIA. |
Country Status (2)
| Country | Link |
|---|---|
| MX (1) | MX386944B (en) |
| WO (1) | WO2015199522A1 (en) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5409903A (en) * | 1992-02-18 | 1995-04-25 | Urecap Corporation | Method and compositions for the treatment of H. pylori and dermatitis |
| AT413484B (en) * | 2002-02-26 | 2006-03-15 | Hraschan Jakob | USE OF ZEOLITHES TO REDUCE THE PROPORTION OF LACTATES IN THE HUMAN AND ANIMAL ORGANISM |
| DE102005053090A1 (en) * | 2005-11-04 | 2007-05-10 | Hubert Danz | Use of an activated zeolite as a pharmaceutical agent for the reduction of toxic substances |
-
2014
- 2014-06-23 WO PCT/MX2014/000095 patent/WO2015199522A1/en active Application Filing
- 2014-06-23 MX MX2017000150A patent/MX386944B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX386944B (en) | 2025-03-19 |
| WO2015199522A1 (en) | 2015-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2016002517A1 (en) | Use of r-2-4-2-ethoxy-3-4-trifluoromethylphenoxypropyl-thio-2-methylphenoxy acetic acid or a salt thereof in the manufacture of a medicament to treat a condition that is a non-alcoholic fatty liver disease or non-alcoholic steatohepatitis. | |
| EP4218816A3 (en) | Pharmaceutical composition for use in prevention and/or treatment of disease that develops or progresses as a result of decrease or loss of activity of blood coagulation factor viii and/or activated blood coagulation factor viii | |
| CR20150376A (en) | REPLACED PIRROLOPIRIMIDINE COMPOUNDS, SAME COMPOUNDS AND TREATMENT METHODS WITH THE SAME | |
| MX2019008085A (en) | Activin-actrii antagonists and uses for treating bone and other disorders. | |
| EA201590058A1 (en) | ANALOGUE GLUACAGONA | |
| NZ757815A (en) | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity | |
| CL2017000866A1 (en) | Compounds and compositions for the treatment or prevention of pathological disorders associated with excess deposition of fibrin and / or thrombus formation | |
| WO2015123423A3 (en) | Methods for treating patients with hypercholesterolemia that is not adequately controlled by moderate-dose statin therapy | |
| CL2016002073A1 (en) | Process to produce an injectable solution of stable low concentration norepinephrine | |
| MX2016008429A (en) | DERIVED FROM PIRANOCROMENIL PHENOL, AND PHARMACEUTICAL COMPOSITION TO TREAT A METABOLIC SYNDROME OR INFLAMMATORY DISEASE. | |
| EA201691918A1 (en) | PHARMACEUTICAL COMPOSITIONS OF KINAZ INHIBITOR KINAZ OF THE RAF FAMILY, METHODS OF THEIR PRODUCTION AND METHODS OF THEIR USE | |
| MX2016015437A (en) | COMBINATION THAT INCLUDES A GLUCOCORTICOID AND EDO-S101. | |
| MX2017003780A (en) | PHARMACEUTICAL COMPOSITION TO TREAT ULCERATIVE COLITIS. | |
| WO2014153009A3 (en) | Thiosaccharide mucolytic agents | |
| EA201790912A1 (en) | Heterocyclic Compound | |
| EA202091446A1 (en) | METHODS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | |
| MX367926B (en) | Pharmaceutical composition for a sustained release of lanreotide. | |
| MX2016010892A (en) | Agent for improving or preventing progression of chronic kidney disease. | |
| CO6731081A2 (en) | Method for producing and using a copolymer of sodium carboxymethylcellulose and gosipol | |
| EA201790973A1 (en) | A-ANTAGONIST IN LOW DOSAGE FOR ADHD TREATMENT AND PARKINSON'S DISEASE | |
| MX2017000150A (en) | ZEOLITE ACTIVATED AND MICRONIZED, AS A COADYUVANT IN THE TREATMENT OF UREMIA. | |
| EA201491455A1 (en) | EFFECTORS β-ARRESTINA, COMPOSITIONS, THEIR CONTAINING, AND METHODS OF THEIR USE | |
| MX2016015303A (en) | Cough medicine containing ambroxol hydrochloride. | |
| EA201892048A1 (en) | PHARMACEUTICAL COMPOSITION, CONTAINING EMAGAGLIFLOZIN, AND ITS APPLICATIONS | |
| EA201991119A1 (en) | PHARMACEUTICAL COMPOSITION, METHODS OF TREATMENT AND ITS APPLICATION |